-
Mashup Score: 0TECLISTAMAB, A B-CELL MATURATION ANTIGEN (BCMA) × CD3 BISPECIFIC... by Niels WJC van de Donk - 2 year(s) ago
EHA Library; WJC van de Donk N. Jun 9 2021; 324601;
Source: library.ehaweb.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 3How does COVID-19 impact patients with lymphoma receiving B-cell-depleting immunotherapy? - 2 year(s) ago
During the EHA2021 Virtual Congress, the Lymphoma Hub spoke with Caroline Besson, Université de Paris, Paris, FR. We asked, How does COVID-19 impact patients with lymphoma receiving B-cell-depleting immunotherapy?
Source: lymphomahub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
👀 Have you seen this? 📹 During #EHA21, the #LymphomaHub spoke with Caroline Besson, @Univ_Paris. We asked, How does #COVID19 impact patients with #lymphoma receiving B-cell-depleting immunotherapy? 👉 https://t.co/n1WwM8Er9k 👈 #lymsm #COVID19SES https://t.co/QIwHsaLkNv
-
-
Mashup Score: 3Is it time to tailor treatment on the basis of minimal residual disease in multiple myeloma? - 2 year(s) ago
Stefania Oliva
Source: The Lancet HaematologyCategories: Latest Headlines, Oncologists2Tweet-
It was great fun to debate the role of #MRD for tailoring treatment in #myeloma with Dr Stefania Oliva at #EHA21 @EHA_Hematology . For those who missed it, a more detailed, written debate on this topic now out in @TheLancetHaem #mmsm https://t.co/lYyAGTPnOv https://t.co/ZpEmJl29Hz
-
-
Mashup Score: 1EHA 2021: real-world data on myeloma, lymphoma and CLL - 3 year(s) ago
Real-world data gained through scientific studies is essential in the advancement of treatments for all hematological malignancies. Historically, pharmaceutical companies…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
💥 Don't miss our new podcast highlighting the most exciting #RealWorldData from the #EHA21 meeting 💥 w/ experts Andrea Visentin, Elena Zamagni, David Miklos & Heinz Ludwig! 👩⚕️👨⚕️ 🎧 Listen now: https://t.co/Tq3OB3H5j6 #VJSounds #CLLsm #MMsm #LYMsm #LEUsm #Lymphoma #Leukemia
-
-
Mashup Score: 0EHA 2021: real-world data on myeloma, lymphoma and CLL - 3 year(s) ago
Real-world data gained through scientific studies is essential in the advancement of treatments for all hematological malignancies. Historically, pharmaceutical companies…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#VJSounds | #EHA21: real-world data on #Myeloma, #Lymphoma and CLL Hear the most exciting #RealWorldData updates presented at this year's EHA meeting from leading experts! 👨⚕️👩⚕️ 🎧 Listen now: https://t.co/7ByvffA3mD @VJHemOnc #LYMsm #LEUsm #MMsm #CLLsm #Leukemia
-
-
Mashup Score: 0
Marina Kremyanskaya, MD, PhD, discussed the results of the phase 2 PTG-300-04 trial, which were presented at the European Hematology Association 2021 Virtual Congress, and the potential for rusfertide as a treatment option for patients with polycythemia vera.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Rusfertide has shown promising efficacy in not only eliminating the need for phlebotomy in patients with PV, but also in improving their quality of life and symptom burden @MKremyanskaya @MountSinaiNYC @EHA_Hematology #EHA21 #oncology #mpnsm https://t.co/koo2sXTP4a https://t.co/JqCWZUn7YM
-
-
Mashup Score: 0
Marina Kremyanskaya, MD, PhD, discussed the results of the phase 2 PTG-300-04 trial, which were presented at the European Hematology Association 2021 Virtual Congress, and the potential for rusfertide as a treatment option for patients with polycythemia vera.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Rusfertide Could Represent New Therapeutic Option in Polycythemia Vera @MKremyanskaya @MountSinaiNYC @EHA_Hematology #EHA21 #oncology https://t.co/37ae231EE0
-
-
Mashup Score: 1
Marina Kremyanskaya, MD, PhD, discussed the results of the phase 2 PTG-300-04 trial, which were presented at the European Hematology Association 2021 Virtual Congress, and the potential for rusfertide as a treatment option for patients with polycythemia vera.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Marina Kremyanskaya, MD, PhD, discussed the results of the phase 2 PTG-300-04 trial and the potential for rusfertide as a treatment option for patients with polycythemia vera @MKremyanskaya @MountSinaiNYC @EHA_Hematology #EHA21 #oncology #mpnsm https://t.co/A3m4g4JMC7
-
-
Mashup Score: 0Quantifying patient and physician preferences in post-HSCT maintenance treatment of AML - 3 year(s) ago
Hematopoietic stem cell transplant (HSCT) in patients with acute myeloid leukemia (AML) is often followed by maintenance therapy to prolong remission. Currently, there are no universally accepted standard maintenance therapies, leaving patients and physicians to determine which treatment to use by assessing the risk/benefit of the different options available.
Source: aml-hub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🩺 Patients with AML and treating physicians prefer different attributes when considering maintenance treatments following HSCT 👉https://t.co/yltDfdAfDU 👈 #EHA21 #amlsm #leusm #leukemia
-
-
Mashup Score: 0Registration - 3 year(s) ago
Country
Source: register.gotowebinar.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Not long until our post-EHA/ICML #LymphomaSession with @gilles_salles @niravshahmd Ulrich Jäger and Stephen Ansell! 🗓 Thurs 29 July at 7pm CEST/6pm BST/1pm EDT📊 Don’t miss your chance to register: https://t.co/vIMf4ckpCO @VJHemOnc #VJSessions #Lymsm #Lymphoma #EHA21 #16ICML https://t.co/EKFrKNCdcG
-
#EHA21 oral presentation Same as #ASCO21 ➡️ https://t.co/pIIsj9ks8a ⭐️pts (n=156) ⭐️cutoff:2/2021 ⭐️ORR:65%, CR or better:~30%, DOR:NR, AEs👇 https://t.co/tLVTYLA3LF